Spectrum of concomitant brain vascular lesions in pediatric diffuse gliomas

Cerebrovascular disease represents a threatening factor for brain cancer survivors. However, a comprehensive evaluation of small vessel disease related to gliomas has not yet been performed. This study aims to characterize concomitant vascular lesions in pediatric diffuse gliomas and identify their association with the molecular subgroup of tumors. We performed a retrospective pathological study of biopsy samples of 77 pediatric patients with diffuse gliomas, treated in Belarusian Research Center for Pediatric Oncology, Hematology and Immunology. Eight molecular subgroups were identified by immunohistochemical and cytogenetic studies (H3K27mut, ALT, IDH1mut, BRAFmut-PXA, FGFR1, BRAFmut/FGFR2, RTK, MYB). In each group microvessel density/area (MVD/MVA), tumor vessels co-option and signs of small vessels disease (SVD) were determined. The levels of microvascularization significantly differed between the molecular subgroups of diffuse gliomas, indicating the presence of intrinsic pro-angiogenic activity there. The highest values of MVD/MVA, as well as rate of hemorrhagic necrosis, were found in the BRAFmut/FGFR2, RTK groups. SVD was common in the adjacent tissues of gliomas and occurred in 32.5 % of cases. High grade SVD was associated with the BRAFmut/FGFR2 and IDH1mut subgroups. BRAFmut/FGFR2 tumors were more aggressive and caused cortical microinfarctions in 84,6 % and leukoaraiosis in 87.5 % of cases. IDH1mut tumors were mainly linked with cortical microinfarctions (60 % of cases). The results of the study suggest that concomitant small vascular lesions are common in adjacent tumor tissue and can significantly influence the overall rate of cerebrovascular disease in convalescents with diffuse gliomas.

1. Kneihsl M., Enzinger C., Wünsch G., Khalil M., Culea V., Urbanic-Purkart T., Payer F., Niederkorn K., Fazekas F., Gattringer T. Poor short-term outcome in patients with ischaemic stroke and active cancer. Journal of Neurology, 2016, vol. 263, no. 1, pp. 150–156. https://doi.org/10.1007/s00415-015-7954-6

2. Lindvig K., Møller H., Mosbech J., Jensen O. M. The pattern of cancer in a large cohort of stroke patients. International Journal of Epidemiology, 1990, vol. 19, no. 3, pp. 498–504. https://doi.org/10.1093/ije/19.3.498

3. Arboix A. Cerebrovascular disease in the cancer patient. Revue Neurologique, 2000, vol. 31, no. 12, pp. 1250–1252.

4. Cestari D. M., Weine D. M., Panageas K. S., Segal A. Z., DeAngelis L. M. Stroke in patients with cancer: Incidence and etiology. Neurology, 2004, vol. 62, no. 11, pp. 2025–2030. https://doi.org/10.1212/01.wnl.0000129912.56486.2b

5. Zhang Y. Y., Chan D. K., Cordato D., Shen Q., Sheng A. Z. Stroke risk factor, pattern and outcome in patients with cancer. Acta Neurologica Scandinavica, 2006, vol. 114, no. 6, pp. 378–383. https://doi.org/10.1111/j.1600-0404.2006.00709.x

6. Müller K., Courtois G., Ursini M. V., Schwaninger M. New insight into the pathogenesis of cerebral small-vessel diseases. Stroke, 2017, vol. 48, no. 2, pp. 520‒527. https://doi.org/10.1161/STROKEAHA.116.012888

7. Moretti R., Caruso P. An iatrogenic model of brain small-vessel disease: post-radiation encephalopathy. International Journal of Molecular Sciences, 2020, vol. 21, no. 18, art. 6506. https://doi.org/10.3390/ijms21186506

8. Fouladi M., Langston J., Raymond Mulhern R., Jones D., Xiong X., Yang J. [et al.]. Silent lacunar lesions detected by magnetic resonance imaging of children with brain tumors: a late sequela of therapy. Journal of Clinical Oncology, 2000, vol. 18, no. 4, pp. 824‒824. https://doi.org/10.1200/JCO.2000.18.4.824

9. Unruh D., Schwarze S. R., Khoury L., Thomas C., Wu M., Chen L. [et al.]. Mutant IDH1 and thrombosis in gliomas. Acta Neuropathologica, 2016, vol. 132, no. 6, pp. 917–930. https://doi.org/10.1007/s00401-016-1620-7

10. Rosser T. L., Vezina G., Packer R. J. Cerebrovascular abnormalities in a population of children with neurofibromatosis type 1. Neurology, 2005, vol. 4, no. 3, pp. 553–555. https://doi.org/10.1212/01.WNL.0000150544.00016.69

11. Kaas B., Huisman T. A., Tekes A., Bergner A., Blakeley J. O., Jordan L. C. Spectrum and prevalence of vasculopathy in pediatric neurofibromatosis type 1. Journal of Child Neurology, 2012, vol. 28, no. 5, pp. 561–569. https://doi.org/10.1177/0883073812448531

12. Zhang L., Kundu S., Feenstra T., Li X., Jin Ch., Laaniste L. [et al.]. Pleiotrophin promotes vascular abnormalization in gliomas and correlates with poor survival in patients with astrocytomas. Science Signaling, 2015, vol. 8, no. 406, art. ra125. https://doi.org/10.1126/scisignal.aaa1690

13. Chiba R., Akiya M., Hashimura M., Oguri Y., Inukai M., Hara A., Saegusa M. ALK signaling cascade confers multiple advantages to glioblastoma cells through neovascularization and cell proliferation. PLoS ONE, 2017, vol. 12, no. 8, p. e0183516. https://doi.org/10.1371/journal.pone.0183516

14. Thon N., Tonn J.-C., Kreth F.-W. The surgical perspective in precision treatment of diffuse gliomas. OncoTargets and Therapy, 2019, vol. 12, pp. 1497‒1508. https://doi.org/10.2147/OTT.S174316

15. Picca A., Berzero G., Sanson M. Current therapeutic approaches to diffuse grade II and III gliomas. Therapeutic Advances in Neurological Disorders, 2018, vol. 11, e1756285617752039. https://doi.org/10.1177/1756285617752039